Can-Fite BioPharma Ltd. (CANF)
↓ Download CSV- Sector Manufacturing
- Incorporated L3
- Fiscal year ends Dec 31
In fiscal 2025, Can-Fite BioPharma Ltd. reported revenue of $405.0K, down 39.9% from the prior year. The company ran a net loss, with a net margin of -2426.7%.
Key ratios (FY2025)
-2456.8%
Operating margin
-2426.7%
Net margin
-175.8%
Return on equity
-39.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $405.0K | $674.0K | $743.0K | $810.0K | $853.0K | $763.0K | $2.03M | $3.82M | $789.0K | — |
| Operating Income | -$9.95M | -$8.13M | -$8.20M | -$10.10M | -$12.84M | -$14.14M | -$12.01M | -$5.41M | -$7.18M | — |
| Net Income | -$9.83M | -$7.88M | -$7.63M | -$10.17M | -$12.62M | -$14.44M | -$12.62M | -$6.57M | -$4.84M | — |
| EPS (Diluted) | $-5.97 | $-10.86 | $-17.92 | $-0.01 | $-0.03 | $-0.04 | — | — | — | — |
| Total Assets | $9.51M | $9.12M | $9.99M | $9.28M | $20.25M | $9.52M | $8.17M | $7.95M | — | — |
| Shareholders' Equity | $5.59M | $5.44M | $6.24M | $4.47M | $14.38M | $6.07M | $2.44M | $3.02M | $2.98M | — |
| Cash & Equivalents | $5.53M | $4.83M | $4.28M | $2.98M | $4.39M | $8.27M | $2.70M | $3.62M | $3.50M | $8.12M |
| Operating Cash Flow | -$8.95M | -$7.64M | -$8.44M | -$10.80M | -$9.86M | -$12.06M | -$11.08M | -$4.16M | -$8.97M | — |
| Capital Expenditures | $2.0K | $5.0K | $2.0K | $9.0K | $11.0K | $26.0K | $3.0K | $33.0K | $7.0K | — |
| Shares Outstanding | 2.62M | 994.4K | 1.36B | 815.75M | 815.75M | 463.77M | 120.65M | 40.40M | — | — |